Changes in hepatic triglyceride content with the activation of ER stress and increased FGF21 secretion during pregnancy

Jiayu Lu1,3,4†, Ying Gong2,3,4†, Xinhong Wei5, Zhenyu Yao2,3,4, Rui Yang6, Jinxing Xin1,3,4, Ling Gao3,4,7 and Shanshan Shao1,3,4*

Abstract

Background: To meet the needs of foetal growth and development, marked changes in lipid profiles occur during pregnancy. Abnormal lipid metabolism is often accompanied by adverse pregnancy outcomes, which seriously affect maternal and infant health. Further understanding of the mechanism of lipid metabolism during pregnancy would be helpful to reduce the incidence of adverse pregnancy outcomes.

Methods: Pregnant mice were euthanized in the virgin (V) state, on day 5 of pregnancy (P5), on day 12 of pregnancy (P12), on day 19 of pregnancy (P19) and on lactation day 2 (L2). Body weight and energy expenditure were assessed to evaluate the general condition of the mice. Triglyceride (TG) levels, the cholesterol content in the liver, liver histopathology, serum lipid profiles, serum β-hydroxybutyrate levels, fibroblast growth factor-21 (FGF21) levels and the levels of relevant target genes were analysed.

Results: During early pregnancy, anabolism was found to play a major role in liver lipid deposition. In contrast, advanced pregnancy is an overall catabolic condition associated with both increased energy expenditure and reduced lipogenesis. Moreover, the accumulation of hepatic TG did not appear until P12, after the onset of endoplasmic reticulum (ER) stress on P5. Then, catabolism was enhanced, and FGF21 secretion was increased in the livers of female mice in late pregnancy. We further found that the expression of sec23a, which as the coat protein complex II (COPII) vesicle coat proteins regulates the secretion of FGF21, in the liver was decreased on P19.

Conclusion: With the activation of ER stress and increased FGF21 secretion during pregnancy, the hepatic TG content changes, suggesting that ER stress and FGF21 may play an important role in balancing lipid homeostasis and meeting maternal and infant energy requirements in late pregnancy.

Keywords: Endoplasmic reticulum stress, FGF21, Pregnancy, Lipid metabolism

Background

Pregnancy (or gestation) is the development of one or more offspring, known as embryos or foetuses, within the maternal uterus. To meet the needs of foetal growth and development, marked changes in lipid profiles occur during pregnancy [1]. During early pregnancy, anabolism plays a major role in augmented lipid deposition in most maternal tissues, which is associated with both hyperphagia and increased lipogenesis. In contrast, advanced pregnancy is an overall catabolic state that involves the accelerated breakdown of fat depots, hyperlipidaemia and insulin resistance [2]. In rats, all depots of the...
maternal body showed an increase in fat content, and the enlarged subcutaneous fat depot was found to account for the largest proportion of total stored fat (36%) [3]. In 1994, Sohlstrom A et al. found that the liver fat content in rats on day 14 of gestation was increased by nearly 20% compared with that in virgin (V) controls [4]. More importantly, abnormal levels of lipids and their metabolites during pregnancy are related to adverse neonatal outcomes [5].

To meet the energy and resource demands of reproduction, a series of changes take place; these changes include an increase in the capacity of the gastrointestinal tract [6] and an obvious increase in the level of lipoprotein lipase, which controls fat uptake by adipose tissue [2]. The liver, the central organ for lipid metabolism, plays a vital role in regulating the production and clearance of lipids. Therefore, changes in liver lipid metabolism are also expected during pregnancy. A previous study reported that the lipid uptake and transport capacities of liver cells and triglyceride (TG) secretion levels are increased throughout reproduction [7]. Moreover, liver X receptor (LXR) targets contribute to lipogenesis during early pregnancy by increasing hepatic expression of the lipogenic enzymes fatty acid synthase (FASN) and stearoyl-CoA desaturase 1 (SCD1) [8]. However, the current understanding of liver lipid metabolism during pregnancy is inadequate. Importantly, the changes that occur in the levels of regulatory factors throughout the entire pregnancy period have not been reported.

Perturbations in endoplasmic reticulum (ER) homeostasis interfere with protein folding in the ER leading to ER stress, which in turn activates the unfolded protein response (UPR) [9, 10]. BIP was the first ER-resident protein involved in protein folding shown to bind incompletely assembled immunoglobulin (Ig) intermediates and to be bound by three principal transmembrane sensors. The UPR is activated via three pathways: the inositol-requiring enzyme (IRE)-1α, protein kinase R-like ER kinase (PERK), and activating transcription factor (ATF)-6α pathways [11, 12]. Much evidence suggests that ER stress is a common feature of fatty liver [13–16]. A study reported five years ago greater expression of PERK and X-box binding protein 1 (XBP1), which are related to ER stress, in the bovine liver two weeks before calving [17]. Moreover, the mRNA levels of XBP1, an ER stress-induced UPR marker, in the liver were found to suddenly increase at calving [18]. Therefore, the UPR may be an important regulator of lipid metabolism during pregnancy.

Fibroblast growth factor-21 (FGF21) was identified in 2000 and named based on its membership in the FGF family [19]. While conventional FGFs act through an autocrine or paracrine mechanism, FGF21 belongs to an FGF subfamily whose members have hormone-like actions [20]. Serum FGF21, which is mostly secreted by the liver, can be delivered to the pancreas or adipose tissue and cause a series of effects such as weight loss and improved insulin sensitivity. A relationship between FGF21 and hepatic lipid metabolism has been described in mice. Knockdown of FGF21 was shown to contribute directly to liver steatosis through inhibition of β-oxidation [21]. Recently, it was shown that the level of the novel metabolic hormone FGF21 increased suddenly at the onset of lactation in dairy cows or during late pregnancy in mice [22, 23]. We speculated that the change in FGF21 secretion during pregnancy is related to liver lipid metabolism.

In this study, we verified the presence of pronounced ER stress in early pregnancy and a sharp increase in FGF21 secretion in late pregnancy and showed that hepatic FGF21 secretion is associated with the coat protein sec23a of coat protein complex II (COPII) vesicles. Moreover, we suspect that the activation of ER stress plays an important role in augmenting hepatic lipid deposition during early pregnancy and that an increase in hepatic FGF21 secretion is crucial in curbing the continuous increase in lipid content during late pregnancy.

Materials and methods

Animals

Female C57BL/6 mice (7–8 weeks old) were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd., and housed in a room with controlled temperature of 22–24 °C under a 12 h light/dark cycle. All mice were fed and allowed to acclimatize for one week. The mice were mated with male breeders or kept in the virgin state. Pregnancy was confirmed by identification of a vaginal plug (the day that the vaginal plug was found was assumed to be day 1 of pregnancy). Subsets of mice were euthanized in the virgin state (V), on day 5 of pregnancy (P5, early pregnancy), on day 12 of pregnancy (P12), on day 19 of pregnancy (P19, late pregnancy) and on lactation day 2 (L2) [7, 8, 23, 24]. This animal study was reviewed and approved by the Animal Ethics Committee (LCYJ: No. 2018–017) of Shandong Provincial Hospital, China.

Assessment of mouse body metabolism using metabolic chambers

Mice were acclimated to an animal monitoring chamber (PhenoMaster, TSE Systems, Germany) for 24 h and then placed in individual metabolic chambers on days 17, 18 and 19 of pregnancy. Afterwards, oxygen consumption \( \left(V_{O_2}\right) \), carbon dioxide production \( \left(V_{CO_2}\right) \), the respiratory
exchange rate (RER) and heat production were simultaneously measured for 2 days.

Sample collection and preservation
After all mice had been fasted for 6 h and anaesthetized with 1% pentobarbital sodium, blood was collected from the mice by eyeball extirpation. Then, the serum was isolated after centrifugation at 3000 rpm for 15 min. The livers were divided into several parts which were fixed for two days in a 4% paraformaldehyde solution or flash frozen in liquid nitrogen and then stored in liquid nitrogen or at −80 °C for subsequent analyses.

Biochemical analysis
Serum TG, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), nonesterified fatty acid (NEFA) and β-hydroxybutyrate (β-HB) levels were measured using a Beckman Chemistry Analyser AU5800 System (Beckman Coulter, Tokyo, Japan). The level of serum FGF21 was measured using commercial immunoassay kit (mouse FGF-21 ELISA kit, Abcam, ab212160). The absorbance at 450 nm was determined using an ELISA microtiter plate reader (BioTek Inc., Winooski, VT, USA).

Hepatic lipid content assay
Lipid extraction was performed as previously described [25]. Briefly, liver homogenates were prepared with liver tissues of the same weight after heating at 70 °C for 10 min and then centrifuged at room temperature at 2000 rpm for 5 min. Hepatic TG, TC and free cholesterol (FC) contents were measured using commercial kits (Applygen Technologies Inc. Beijing, China), and the values were normalized to the weight of the liver tissue by gram.

Histology
Liver tissues fixed in a 4% paraformaldehyde solution were used for haematoxylin and eosin (H&E) staining. Tissue blocks were routinely dehydrated in graded alcohol, cleared with xylene, embedded in paraffin and cut into 5 μm slices. Frozen sections were used for oil red O staining. The tissue blocks were cut into 10 μm slices, then stained with oil red O for 10 min, washed, and counterstained with haematoxylin for 2 min. All pathological images were observed using a system incorporated in a microscope (Axiovert 100 M Zeiss, Germany).

RNA isolation and quantitative real-time PCR (Q-PCR)
Total RNA was isolated from the liver tissue using RNAsio Plus reagent (Takara, Japan) according to the manufacturer’s instructions. RT reactions were carried out using a PrimeScript RT reagent kit (TaKaRa). Real-time PCR was performed using the Roche 480 detection system and SYBR Green mix (Bestar qPCR Mastermix, DBI, Germany) following the manufacturer’s protocol. β-Actin was employed as an endogenous control. Relative gene expression levels were quantified using the 2-ΔΔCt method, and the results are expressed as the fold change relative to the control. The PCR primers used are listed in Table 1.

RT2 PCR array
RNA extracted from the livers of mice in the V state and mice in late pregnancy were subjected to analysis with the Mouse Fatty Liver RT2 Profiler PCR Array (PAMM-157Z, Qiagen). The 96-well plate array was assessed using a Light Cycler 480 system (Roche) according to the manufacturer’s instructions to examine the expression of 84 genes related to fatty liver disease. Variations in gene expression between mice in late pregnancy and mice in the V state are expressed as fold changes. A detailed description of this PCR array can be found online (https://geneglobe.qiagen.com/cn/product-groups/rt2-profiler-pcr-arrays). The method for analysis of the liver RT2 Profiler PCR array was described in a previous study in our laboratory and another study [26, 27].

Western blot analysis
Mouse liver tissues were homogenized in RIPA buffer with protease and phosphatase inhibitors (Bimake, Houston, USA). The protein concentration was determined using a BCA Protein Quantitative Assay Kit (Shenergy Biocolor Bioscience & Technology Co., Shanghai, China). Total protein was mixed with SDS loading buffer and subjected to SDS-PAGE on a 10% gel. Proteins were electrotransferred onto PVDF membranes (Millipore) and the blots were probed with the following primary antibodies overnight at 4 °C: anti-FASN (cst3180, Cell Signaling Technology, USA), anti-SREBP1C (ab3259, Abcam, USA), anti-SCD1 (ab19862, Abcam), anti-CPT1α (ab176320, Abcam), anti-MTP (sc-135994, Santa Cruz Biotechnology, USA), anti-CD36 (18836-i-ap, Proteintech, China), anti-FGF21 (ab171941, Abcam), anti-BIP (11587-1-ap, Proteintech), anti-p-IRE (ab48187, Abcam), anti-IRE (ab37073, Abcam), anti-ELF2α (cst9722, Cell Signaling Technology), anti-p-ELF2α (cst3597, Cell Signaling Technology), anti-ATF4 (10835-1-ap, Proteintech), anti-ATF6 (ab122897, Abcam), anti-p-PERK (sc-32577, Santa Cruz Biotechnology), anti-PERK (ab65142, Abcam).
Table 1 (continued)

| Gene   | GenBank ID | Primer sequence (5′ – 3′)                  |
|--------|------------|---------------------------------------------|
| Sec31a | 69,162     | Forward TGACAGAGTGCCGCAAGAGAAGA               |
|        |            | Reverse TGGTAGCTGATGAAGGAAACAGG              |
| Sec3c  | 10,379     | Forward TGGACACTGTGGGACCAGCTCT               |
|        |            | Reverse TGGAGCCCATCTGAGGAGG                  |
| β-actin| 11,461     | Forward ACCCAACCGATGTCAGTGCG               |
|        |            | Reverse GTTGAGTGACCCGGTCCT                  |

and anti-GAPDH (60,004–1, Proteintech). Appropriate secondary antibodies conjugated to horseradish peroxidase (Amersham) were diluted 1:5000 used. The bound primary antibodies were visualized using the Alpha Q detection system.

Statistical analyses

All data are expressed as the means ± SEMs. Statistical significance was analysed using either two-tailed unpaired Student’s t-tests (for two groups) or one-way ANOVA (for multiple groups). The data were analysed using SPSS 24.0 software. p < 0.05 was used to indicate statistical significance.

Results

Alterations in body energy expenditure, serum lipid levels and hepatic fat content during pregnancy

Gestation led to both body and liver weight gain especially during advanced pregnancy. Female mice showed a very rapid reduction in body weight after birth, while their liver weight was not significantly changed (Fig. 1a).

To evaluate the effect of gestation on body energy metabolism, energy expenditure was measured using metabolic chambers. Compared with mice in the V group, mice in the P17-19 group, showed increased VO2, VCO2, and heat production, and a decreased RER, which indicated β-oxidation was enhanced (Table 2). Moreover, the serum lipid levels of the mice differed during different gestation periods. TC and HDL-C levels reached a minimum in the P12 group and then gradually rose (Fig. 1b).

To further examine the potential alterations in lipid levels in the liver, we used a hepatic lipid content assay and found that the hepatic cholesterol content rose in the P19 group but decreased in the L2 group (Fig. 1d, e), which differs from observations in humans; thus, these mice are not a good model of pregnancy in humans in which to study cholesterol metabolism. Then, we measured the TG level, which was obviously increased in the P12 and P19 groups compared to the V group (Fig. 1c); additionally, a significant increase in hepatic TG content was observed in the P12 and P19 groups (Fig. 1f). Consistently, more lipid droplets and ballooning degeneration were observed during pregnancy.
Fig. 1 The effect of pregnancy on body weight, liver weight, the serum lipid profiles and lipid profiles of the liver. (a) Body weight and liver weight during pregnancy or lactation. (b) Serum TC, LDL-c and HDL-c levels. (c) Serum TG and NEFA levels. (d-f) TG content, TC content and FC content in the liver normalized by liver tissue weight in grams (n = 9–12 per group). (g) First row: Representative gross morphology of the uterus. Second row: Representative gross morphology of the liver. Third row: Representative images of H&E-stained liver tissue (magnification, 200 ×). Last row: Representative images of oil red O-stained liver tissue (magnification, 400 ×). Each bar represents the mean ± SEM of the indicated variable. Statistical analyses were performed with one-way ANOVA. *P < 0.05, **P < 0.01 versus the V or P19 group; ns, not significant.
in the liver during late pregnancy, as shown by H&E and oil red O staining (Fig. 1g).

Throughout pregnancy, the expression of TG metabolism genes followed a distinct biphasic pattern
To further study the lipid metabolism mechanism during pregnancy, microarray analysis was performed to identify changes in murine hepatic gene expression between the late pregnancy groups and V group; we found that the expression of a set of lipid synthesis-related genes, including SCD1 and FASN, was downregulated in the late pregnancy group. The most striking change in lipid synthesis-related genes was the change in SCD1, the expression of which was markedly downregulated 19-fold in the late pregnancy group compared with the V group (Fig. 2a, b). The qPCR results were consistent with these findings. In early pregnancy, consistent with the early-gestational increase in hepatic TG levels, the mRNA and protein levels of the lipogenic targets FASN and SREBP1C were markedly increased. In contrast, during late pregnancy, the mRNA and protein levels of SREBP1C, FASN and SCD1 were substantially diminished (Fig. 2a, b), which is consistent with the lack of a change in liver TG levels between P12 and P19 (Fig. 1f). In addition, the livers of the mice exhibited high lipid uptake and secretion, and liver transport ability was enhanced during pregnancy, as indicated by changes in expression of the related genes CD36, FABP1, FATP2 and FATP5 revealed by microarray analysis, qPCR and western blot analysis (Fig. 2a, b).

In addition, western blot analysis revealed that the gene expression of BIP and phosphorylation levels of IRE, PERK and eIF2a were increased in the P5 group compared to the V, P12 and P19 groups (Fig. 2c), indicating the possible activation of all three branches of ER stress during early pregnancy. Activation of any pathway of the ER stress response is an important cause of nonalcoholic steatohepatitis. We further found that the accumulation of hepatic TG did not occur until P12 (Fig. 1f), after the onset of overt ER stress, suggesting that ER stress may be involved in the accumulation of hepatic TG during pregnancy.

Catabolism was enhanced with increased FGF21 secretion in the livers of female mice in late pregnancy
Levels of the β-oxidation related genes CPT1α, hadha, ACOX1, Ech1, Ehhadh and Mlycd, increased during late pregnancy (Fig. 3a), demonstrate that catabolism was dominant over anabolism. In addition, metabolic chamber analysis showed a decrease in RER in late pregnancy (Table 2). RER, the ratio of carbon dioxide produced to oxygen consumed, reflects the substrate consumed by the energy supply. With enhanced fatty acids oxidation, the RER decreases. Therefore, the metabolic chamber analysis results suggest that fatty acid oxidation in the liver was significantly enhanced.

In the livers of pregnant mice, fatty acid oxidation produces ketone bodies, the most important energy source for the foetus in the absence of a glucose supply. We found that the level of β-hydroxybutyrate, an important ketone body, was significantly increased in late pregnancy (Fig. 3b). In a ketotic state, the serum FGF21 level increased from slightly over 100 pg/ml in the V group to nearly 6000 pg/ml in the P19 group and had returned to the level in the V group by L2 (Fig. 3c). Furthermore, the mRNA expression of FGF21 significantly increased more than 30-fold at P19 and then returned to its former level at L2 (Fig. 3d). Surprisingly, hepatic FGF21 was almost undetectable in late pregnancy (Fig. 3e), which may have been related to increased FGF21 secretion. Therefore, we measured the gene expression of Yipf6, Yipf5, Sarla, Sec23a, Sec24a, Sec31a and Sec13 in secretory vesicles in the ER and Golgi [28]. The level of only sec23a, a small GTPase that initiates COPII coat assembly, was detected in late pregnancy (Fig. 3f). Moreover, the levels of the βKlotho (KLB) gene and the FGFRs genes FGFR1, FGFR2, FGFR3 and FGFR4 were measured. The expression levels of these genes, except FGFR3, were not affected by pregnancy (Fig. 3g).

Table 2 Alterations in energy expenditure during pregnancy

|                      | Non-pregnant V | Late pregnancy P17-19 |
|----------------------|----------------|----------------------|
| \( V_{O_2} \) (ml/h) |                |                      |
| Light (12 h)         | 76.163 ± 0.525 | 104.413 ± 2.522**    |
| Dark (12 h)          | 82.856 ± 0.422 | 108.279 ± 1.073**    |
| Whole day (24 h)     | 79.714 ± 0.234 | 106.464 ± 1.028**    |
| \( V_{CO_2} \) (ml/h)|                |                      |
| Light (12 h)         | 69.098 ± 0.540 | 88.522 ± 1.547**     |
| Dark (12 h)          | 78.779 ± 0.818 | 100.346 ± 1.135**    |
| Whole day (24 h)     | 74.235 ± 0.583 | 94.796 ± 1.043**     |
| Heat production (kcal/h) |              |                      |
| Light (12 h)         | 0.376 ± 0.003  | 0.509 ± 0.012**      |
| Dark (12 h)          | 0.414 ± 0.002  | 0.538 ± 0.005**      |
| Whole day (24 h)     | 0.396 ± 0.002  | 0.524 ± 0.005**      |
| RER                  |                |                      |
| Light (12 h)         | 0.906 ± 0.003  | 0.849 ± 0.007**      |
| Dark (12 h)          | 0.948 ± 0.010  | 0.924 ± 0.009        |
| Whole day (24 h)     | 0.928 ± 0.005  | 0.889 ± 0.002**      |

Results are represented as mean ± SEM (n = 6–8) *p < 0.05, **p < 0.01, comparison of late pregnancy groups (P17-19) versus non-pregnant group (V). P value determined by unpaired t-test.
Discussion
Our main finding is that during early pregnancy anabolism plays a major role in augmenting hepatic lipid deposition, but advanced pregnancy is an overall catabolic state involving the accelerated breakdown of fat depots in the liver and hyperlipidaemia. Our study revealed that ER stress is a novel regulator during early pregnancy and that the increase in hepatic FGF21 secretion during late pregnancy is associated with Ses23a, a coat protein of COPII vesicles. Moreover, finding related to the novel hormone FGF21 will provide important insights into decreasing lipids and their metabolites during pregnancy to ensure maternal and child health.

Our results, established that gestation contributes to an increase in hepatic TG content in advanced pregnancy, and mice in the P12 and P19 groups exhibited...
larger lipid droplets than mice in the V group. We then assessed the metabolic rate, expressed as continuous VO2 consumption with a marked increase in VCO2 exhalation across a 24-h period, and found that body energy consumption was greatly increased during late pregnancy. In addition, increased heat production was confirmed. Notably, the RER was decreased, and more serum β-HB was produced, indicating an increase in fatty acid β-oxidation and a decrease in the amount of stored fat in late pregnancy compared to the V state. In summary, more lipids and fewer carbohydrates were oxidized in late pregnancy. TG accumulation in the
liver likely suggests a balance between hepatic TG de novo lipogenesis, β-oxidation, and fatty acid uptake and secretion [29]. Notably, the lipid synthesis-related gene that showed the most striking decrease was SCD1, which regulates TG metabolism. The sharp drop in the expression of the lipid synthesis-related gene SCD1 and increase in expression of the β-oxidation-related genes CPT1α, hadha, ACOX1, Ech1, Ehhdah and Mlycd reflect the dominance of hepatic lipid catabolism in late pregnancy, providing lipids for foetal growth and development.

Previous studies have illustrated a simple relationship between ER stress and TG metabolism. The ER stress response was first discovered in nonalcoholic steatohepatitis, which is induced by genetics or diet [30]. The PERK-eIF2α pathway in ER stress has been reported to regulate lipogenesis and lipogenic differentiation, and deletion of PERK inhibited continuous expression of the lipogenic enzymes FASN and SCD1 [31]. Liver-specific knockout of IRE1α triggered severe hepatic steatosis after treatment with an ER stress inducer and suppressed the expression of key metabolic transcriptional regulators involved in TG biosynthesis [32]. ATF6α-knockout mice showed lower fatty acid β-oxidation, attenuated very-low-density lipoprotein (VLDL) formation and increased hepatic steatosis in response to an ER stress inducer [33]. Importantly, ER stress occurred earlier than hepatic TG accumulation in our pregnant mouse model. Therefore, we conclude that pronounced ER stress during early pregnancy is related to hepatic TG accumulation (Fig. 4).

Numerous hormones and nuclear receptors contribute to the regulation of hepatic lipid homeostasis [34–36]. Hormone levels change dramatically during pregnancy, and hormones are important factors related to changes in liver TG metabolism in this period. Oestrogen has been shown to contribute directly to alleviating fatty liver by disrupting insulin’s effects, promoting liver fat storage, reducing oxidative damage, and inhibiting TG synthesis [37, 38]. Prolactin inhibits hepatic steatosis by the CD36 pathway and reduces SCD1 gene expression [39, 40]. FGF21, a novel metabolic hormone is involved in coordinating diverse metabolic pathways to control glucose and lipid metabolism [19, 41]. In the mouse, FGF21 production is triggered by a flux of free fatty acids reaching the liver, arising from either the mobilization of lipid stores or consumption of a ketogenic diet [42, 43]. At present, the main regulatory factors of FGF21 that have been reported are PPARα and STAT5, which activate transcription of the FGF21 gene [44, 45]. On the other hand, the COPII coat is generated by a flexible vesicle formation system that drives ER export to the Golgi [46]. In this study, we found that the gene expression level of the Sec23a gene was increased, which has been confirmed to ensure the coordination of COPII vesicle trafficking and direction of ER–Golgi trafficking [47, 48]. Therefore, we hypothesize that the increase in FGF21 levels may induce a significant reduction in TG levels during late pregnancy (Fig. 4).

Interestingly, studies have shown that ER stress and FGF21 are strongly associated and inhibit one another [49]. We hypothesized that ER stress was dominant in early pregnancy while FGF21 synthesis was inhibited, causing the levels of lipid biosynthesis-related molecules to be increased in the livers of pregnant mice. However, FGF21 synthesis and secretion were then dominant; thus, fatty acid oxidation was enhanced in the livers of the pregnant mice, and liver lipid accumulation was no longer increased.

In addition to the abovementioned findings, insulin plays an important role in the regulation of glucose balance and metabolic homeostasis. Insulin stimulates glucose utilization; promotes protein synthesis and hepatic and muscle glycogenesis; and inhibits glucagon secretion, glycosogenolysis and lipolysis [50]. Insulin-resistant individuals exhibit increased de novo lipogenesis and re-esterification, inducing fat accumulation in the liver [51]. According to reports in humans, total body insulin sensitivity is reduced by 45–70% in mid-to-late gestation [52, 53]. Studies in rodents also demonstrated that serum insulin level during late pregnancy gradually increased to approximately double that of the V state [54, 55]. Presumably, the results in our mice were similar, the serum insulin level increased in late pregnancy and may have contributed to increased TG accumulation in the liver in the P12 group. Notably, despite continuously increased insulin resistance, the hepatic TG content in the P19 group did not increase after P12. The sharp increase in FGF21 at P19 might be responsible for this.

The placenta is a major endocrine organ, and placental hormones have diverse and profound effects on maternal physiology and metabolism that should not be ignored. Experimental data from rodent models indicate that placental lactogen and prolactin can stimulate maternal beta cell proliferation during early gestation, increasing insulin secretion and aiding fat deposition [52]. Later in pregnancy, placental lactogen and growth hormone contribute to maternal insulin resistance and concomitantly increase de novo lipogenesis and re-esterification, inducing fat accumulation in the liver [53]. Thus, we cannot exclude the possibility that placental hormones and maternal hormones such as oestrogen, prolactin and insulin participate in hepatic TG metabolism in pregnancy.

As presented in this article, the main innovative finding of our study is the observation of changes in hepatic ER stress and FGF21 secretion during pregnancy. We
inferred that ER stress was related to the increase in hepatic lipid content in early pregnancy, and that increased FGF21 secretion was related to the noncontinuous increase in the hepatic lipid content during late pregnancy. In addition, we are the first to use metabolic chambers to evaluate metabolic changes in mice during late pregnancy.

We did not use 4-phenylbutyric acid (4-PBA) to inhibit ER stress or knock down FGF21 in pregnant mice to explore the consequent changes in hepatic TG accumulation, which is a limitation of the present study. The causality of the reported relationship needs to be determined by further research.

**Conclusions**

To the best of our knowledge, this is the first study to evaluate the activation of hepatic ER stress and FGF21 secretion during gestation and lactation. Our

---

**Fig. 4** Schematic of the regulation and potential roles of ER stress and FGF21 in lipid metabolism during pregnancy. Activation of the PERK, IRE and ATF6 ER stress pathways plays an important role in augmenting hepatic TG synthesis and deposition during early pregnancy. A sharp increase in hepatic FGF21 secretion is crucial in curbing the continuous increase in hepatic TG content during late pregnancy, and hepatic FGF21 secretion is associated with the COPII vesicle coat proteins sec23a.
data reveal that the hepatic lipid content increases with the activation of ER stress in early pregnancy and that FGF21 secretion increases during late pregnancy, suggesting that ER stress and FGF21 may play important roles in balancing lipid homeostasis and meeting maternal and infant energy requirements in late pregnancy.

Abbreviations

Aca1b: Acyl-CoA Acyltransferase 1b; ACC1: Acetyl-CoA carboxylase 1; ACOX1: Acyl-CoA oxidase 1; ApoB: Apolipoprotein B; ATP: Activating transcription factor; BIP/GRP78: Immunoglobulin-binding protein; BMI: Body Mass Index; COPII: Coat protein complex II; CPT 1a: Carnitine palmitoyl transferase 1; EcH1: Enolyl-CoA Hydratase 1; Ehhadh: Enolyl-CoA Hydratase and 3-Hydroxyacyl-CoA Dehydrogenase; ELISA: Enzyme-linked immunosorbent assay; ER: Endoplasmic reticulum; FABP1: Fatty acid binding protein 1; FASN: Fatty acid synthase; FAT/CD36: Fatty acid translocase/Cluster of differentiation 36; FATP2: Fatty acid transport protein 2; FATP5: Fatty acid transport protein 5; FC: Free cholesterol; FGF21: Fibroblast growth factor 21; FGR: Fibroblast growth factor receptor; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; Hadha: Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex; HDL-C: High density lipoprotein cholesterol; H&E: Hematoxylin and eosin; ICP: Intrahepatic cholestasis of pregnancy; IRE: Inositol-requiring enzyme; KLB: BKlotho; L: Lactation; LDL-C: Low-density lipoprotein cholesterol; LXR: Liver X receptor; Mlycd: Malonyl-CoA Decarboxylase; MTP: Mitochondrial trifunctional protein; NASH: Non-alcoholic steatohepatitis; NEFA: Non-esterified fatty acid; P: Pregnancy; PCR: Polymerase chain reaction; PERK: Protein kinase RNA-like ER kinase; PPARα: Peroxisome proliferators-activated receptor α; RER: Respiratory exchange rate; RNA: Ribose nucleic acid; SCD1: Stearyl Coenzyme A desaturase 1; SREBP1C: Sterol regulatory element binding protein 1C; TC: Total cholesterol; TG: Triglyceride; UPR: Unfolded protein response; VO2: Oxygen consumption; VCO2: Carbon dioxide production; VLDL: Very low-density lipoprotein; XBP1: X-box binding protein 1; β-BH: β-Hydroxybutyrate; 4-PBA: 4-Phenylbutyric acid.

Acknowledgements

We acknowledge the editors and anonymous reviewers for insightful suggestions on this work.

Authors’ contributions

Design of the study was done by SS, LG and JL. Experiments was performed by JL, JX and YG. Analyses and data mining were performed by JL and ZY. Technical assistances were performed by KW, YG and RI. Interpretation of the obtained information was done by SS, YG and JL. The manuscript was written by JL and was approved by SS. All authors read and approved the final manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (Grant Nos. 81230018, 81471006 and 81430020) and the Medical and Health Technology Development Program in Shandong Province (2016WS0443).

Availability of data and materials

All data generated or analyzed during this study are included in this published paper or are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The animal experimental protocol was approved by the Animal Ethics Committee of Shandong Provincial Hospital affiliated with Shandong First Medical University (Jinan, China).

Consent for publication

All authors support the submission to this journal.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 544, Jing 4 Rd., Jinan 250021, Shandong, China. 2 Department of Endocrinology, Shandong Provincial Hospital, Cheeulo College of Medicine, Shandong University, Jinan 250021, Shandong, China. 3 Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Jinan 250021, Shandong, China. 4 Shandong Institute of Endocrine and Metabolic Disease, Jinan 250021, Shandong, China. 5 Shandong Medical Imaging Research Institute, Shandong University, Jinan 250021, Shandong, China. 6 Experimental Animal Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China. 7 Scientific Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.

References

1. Ghoo A, Bertolotto A, Resi V, Volpe L, Di Ciann G. Triglyceride metabolism in pregnancy. Adv Clin Chem. 2011;55:133-53.

2. Herrera E. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine. 2002;19(1):43-55.

3. Naismith DJ, Richardson DP, Pritchard AE. The utilization of protein and energy during lactation in the rat, with particular regard to the use of fat accumulated in pregnancy. Br J Nutr. 1982;48(2):433-440.

4. Sohlistrom A, Kabir N, Sadurskis A, Forsum E. Body composition and fat distribution during the first 2 weeks of gestation in ad lib fed and energy-restricted rats. Br J Nutr. 1994;71(3):317-329.

5. Kadakia R, Nodzenski M, Talbot O, Kuang A, Bain JR, Muehlhauser MJ, et al. Maternal metabolites during pregnancy are associated with newborn outcomes and hyperinsulinaemia across ancestries. Diabetologia. 2019;62(3):473-84.

6. Speakman JR. The physiological costs of reproduction in small mammals. Philos Trans R Soc Lond B Biol Sci. 2008;363(1490):375-98.

7. Zhang Y, Kallenborg C, Hyatt HW, Kavazis AN, Hood WR. Change in the lipid transport capacity of the liver and blood during reproduction in rats. Front Physiol. 2017;8:517.

8. Nikolova V, Papadopoulos G, Bellafante E, Borges ML, Jansen E, Baron S, et al. Changes in LXR signalling influence early pregnancy lipogenesis and protect against dysregulated fetoplacental lipid homeostasis. Am J Physiol Endocrinol Metab. 2017;313(4):E463-72.

9. Wang S, Kaufman RJ. How does protein misfolding in the endoplasmic reticulum affect lipid metabolism in the liver? Curr Opin Lipidol. 2014;25(2):125-32.

10. Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacol Ther. 2019;203:107401.

11. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 2006;66(2 Suppl 1):S102-9.

12. Gardner BM, Walter P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. Science. 2011;333(6051):1891-4.

13. Esfandiari F, Villanueva JA, Wong DH, French SW, Halsted CH. Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in microogs. Am J Physiol Gastrointest Liver Physiol. 2005;289(1):G64-63.

14. Galligan JJ, Smathers RL, Shearn CT, Fritz KS, Backos DS, Jiang H, et al. Oxidative stress and the ER stress response in a murine model for early-stage alcoholic liver disease. J Toxicol. 2012;2012:207594.

15. Tiedensdromn O, Vacaru AM, Howarth DL, Yin C, Sadler KC. Ethanol metabolism and oxidative stress are required for unfolded protein response activation and steatosis in zebrafish with alcoholic liver disease. Dis Model Mech. 2013;6(5):1213-26.
16. Tsuchiya M, Ji C, Kosyk O, Shymonyak S, Melnyk S, Kono H, et al. Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology. 2012;56(1):130–9.

17. Khan MJ, Jacometro CB, Riboni MV, Trevissi E, Graugnard DE, Correa MN, et al. Stress and inflammatory gene networks in bovine liver are altered by plane of dietary energy during late pregnancy. Funct Integr Genomics. 2015;15(5):563–76.

18. Haga S, Miyaji M, Nakano M, Ishizaki H, Matsuyma H, Kato Y, et al. Changes in the expression of alpha-tocopherol-related genes in liver and mammary gland biopsy specimens of peripartum dairy cows. J Dairy Sci. 2018;101(6):5277–93.

19. Nishimura T, Nakatake Y, Konishi M, Toho N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203–6.

20. Kliever SA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019;29(2):246–53.

21. Badman MK, Pisios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–37.

22. Schoenberg KM, Giesy SL, Harvatine KJ, Waldron MR, Cheng C, Kharitonenkov A, et al. Plasma FGF21 is elevated by the intense lipid mobilization of lactation. Endocrinology. 2011;152(2):4652–61.

23. Cui Y, Giesy SL, Hassan M, Davis K, Zhao S, Boscosl VR. Hepatic FGF21 production is increased in late pregnancy in the mouse. Am J Physiol Regul Integr Comp Physiol. 2014;307(3):R290–8.

24. Sweeney TR, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Decreased nuclear receptor expression in the livers of mice in late pregnancy. Am J Physiol Endocrinol Metab. 2006;290(6):E1313–20.

25. Jia N, Lin X, Ma S, Ge S, Su S, Yang C, et al. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphyllum (Thunb.) Makino treated mice. Nutr Metab (Lond). 2018;15:86.

26. Wang X, Du H, Shao S, Bo T, Yu C, Chen W, et al. Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis. Metab Syndr Relat Disord. 2010;8(1):25–32.

27. Pan QR, Ren YL, Liu WX, Hu YJ, Zheng JS, Xu Y, et al. Resveratrol prevents changes in the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. Nutr Res. 2015;35(7):576–84.

28. Wang L, Mazagova M, Pan C, Yang S, Brandk L, Liu J, et al. YIPF6 controls hepatic triglyceride content through upregulation of SREBP-1c activity. J Biol Chem. 2014;289(46):30948–56.

29. Cao Q, Wang H, Peng F, Sun X, Chu X, et al. Prolactin improves hepatic steatosis through activation of lipogenic genes in livers of CD36/−/− mice. J Physiol 2018;596(12):2765–79.

30. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endo-OSA induces hepatic steatosis and lipid droplet formation in ATF6alpha-unfolded protein response transducer IRE1alpha transduces ER stress-induced hepatic lipid accumulation. Diabetes. 2011;60(7):2424–34.

31. Zhu L, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP, et al. Estrogen treatment after ovarioectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes. 2013;62(2):424–34.

32. Shao S, Yao Z, Lu J, Song Y, He Z, Yu C, et al. Ablation of prolactin receptor increases hepatic triglyceride accumulation. Biochem Biophys Res Commun. 2018;498(3):695–6.

33. Zhang P, Ge Z, Wang H, Feng W, Sun X, Chu X, et al. Prolactin improves hepatic steatosis via CD36 pathway. J Hepatol. 2018;68(6):1247–55.

34. Long YC, Kharitonenkov A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta (BBA) Mol Basis Dis. 2011;1812(7):791–5.

35. Badman MK, Koester A, Flier JS, Maratos-Flier A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150(11):4931–40.

36. Inagaki T, Dutschak P, Zhao G, Ding X, Gautron L, Parente E, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–25.

37. Ludersen T, Hunt MC, Nilsson LM, Sanyal J, Angelin B, Alexson SE, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007;360(2):437–40.

38. Yu J, Zhao L, Wang A, Elessawapu S, Ge X, Chen D, et al. Growth hormone stimulates transcription of the fibroblast growth factor 21 gene in liver. Endocrine. 2012;31(2):750–8.

39. Miller EA, Schekman R. FOP1 - a flexible vesicle formation system. Curr Opin Cell Biol. 2013;25(4):420–7.

40. Fromme JC, Orci L, Schekman R. Coordination of COP1 vesicle trafficking by Sec23. Trends Cell Biol. 2008;18(7):330–6.

41. Lord C, Bhandari D, Menon S, Ghaisemian M, Nyicz D, Hay J, et al. Sequential interactions with Sec23 control the direction of vesicle traffic. Nature. 2011;473(7346):181–6.

42. Jia N, Lin X, Ma S, Ge S, Su S, Yang C, et al. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphyllum (Thunb.) Makino treated mice. Nutr Metab (Lond). 2018;15:86.

43. Fromme JC, Orci L, Schekman R. Coordination of COP1 vesicle trafficking by Sec23. Trends Cell Biol. 2008;18(7):330–6.

44. Lord C, Bhandari D, Menon S, Ghaisemian M, Nyicz D, Hay J, et al. Sequential interactions with Sec23 control the direction of vesicle traffic. Nature. 2011;473(7346):181–6.

45. Jiang S, Yan C, Fang QC, Shao ML, Zhang YL, Liu Y, et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counters endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem. 2014;289(43):29751–65.

46. Das S, Behera MK, Misra S, Balarishna AK. Beta-cell function and insulin resistance in pregnancy and their relation to fetal development. Metab Syndr Relat Disord. 2010;8(1):25–32.

47. Schekman R. COPI - a flexible vesicle formation system. Curr Opin Cell Biol. 2013;25(4):420–7.

48. Fromme JC, Orci L, Schekman R. Coordination of COP1 vesicle trafficking by Sec23. Trends Cell Biol. 2008;18(7):330–6.

49. Lord C, Bhandari D, Menon S, Ghaisemian M, Nyicz D, Hay J, et al. Sequential interactions with Sec23 control the direction of vesicle traffic. Nature. 2011;473(7346):181–6.

50. Fromme JC, Orci L, Schekman R. Coordination of COP1 vesicle trafficking by Sec23. Trends Cell Biol. 2008;18(7):330–6.

51. Titchenell PM, Lazar MA, Birnbaum MJ. Unraveling the Regulation of FGF21 by Insulin. Trends Endocrinol Metab. 2017;28(7):497–505.

52. Newbern D, Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):409–16.

53. Freemark M. Regulation of maternal metabolism by pituitary and placental hormones: roles in fetal development and metabolic programming. Horm Res. 2006;65(Suppl 3):41–9.

54. Lovat N, Legare DJ, Gieni RS, Lautt WW. Gestational postprandial insulin sensitivity in the Sprague Dawley rat: the putative role of hepatic insulin sensitizing substance in glucose partitioning in pregnancy. Can J Physiol Pharmacol. 2020;98(8):541–7.

55. Kondo E, Sugiyama T, Kusaka H, Toyoda N. Adiponectin mRNA levels in plasma are decreased in bovine parametrial adipose tissue and serum adiponectin levels are reduced in cows. J Vet Med Sci. 2002;64(4):313–7.